Sutro Biopharma, Inc. (STRO): Total Liabilities
$306.28M
As of 2025-12-31
$297.78M
As of 2026-06-30
+17.3%
3-year compound annual growth
+37.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $306.28M | -10.6% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $342.61M | +6.7% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $321.09M | +69.1% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $189.90M | +113.7% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $88.84M | +43.2% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $62.06M | +5.9% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $58.58M | -36.0% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $91.60M | +93.8% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $47.27M | n/a | 2019-04-01, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $61.05M | +22.6% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $250.22M | +23.9% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $410.94M | +15.6% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $242.82M | -34.4% |
Compare STRO, IPSC, IBRX, ATRA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗